-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VuFeW+y7D2nU9EDRzC+rq930N6zZjxD6pM/nGsKrcQqhoft6iYNI0d0gSOKRGaol urQQmJtJMPd2VgUaXZxUfA== 0000930413-06-001132.txt : 20060215 0000930413-06-001132.hdr.sgml : 20060215 20060215170927 ACCESSION NUMBER: 0000930413-06-001132 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060215 DATE AS OF CHANGE: 20060215 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: HEMOBIOTECH INC CENTRAL INDEX KEY: 0001301348 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-81482 FILM NUMBER: 06622631 BUSINESS ADDRESS: STREET 1: 2110 RESEARCH ROW STREET 2: SUITE 457 CITY: DALLAS STATE: TX ZIP: 75235 BUSINESS PHONE: 469-585-4613 MAIL ADDRESS: STREET 1: 2110 RESEARCH ROW STREET 2: SUITE 457 CITY: DALLAS STATE: TX ZIP: 75235 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Bollon Arthur CENTRAL INDEX KEY: 0001329091 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: BUSINESS PHONE: (972)620-2245 MAIL ADDRESS: STREET 1: 13227 CEDAR LANE CITY: DALLAS STATE: TX ZIP: 75234 SC 13G 1 c41017_sc13g.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Hemobiotech, Inc. ------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.001 Par Value Per Share ------------------------------------------------------------------------------- (Title of Class of Securities) 42368P102 ------------------------------------------------------------------------------- (CUSIP Number of Class of Securities) May 31, 2005 ------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] RULE 13d-1(b) [ ] RULE 13d-1(c) [X] RULE 13d-1(d) CUSIP NO. 42368P102 Page 2 of 5 - -------------------------------------------------------------------------------- 1) Name And I.R.S. Identification No. Of Reporting Person Arthur Bollon - ------------------------------------------------------------------------------- 2) Check The Appropriate Box If A Member Of A Group (a) [ ] (b) [ ] - ------------------------------------------------------------------------------- 3) SEC Use Only - ------------------------------------------------------------------------------- 4) Citizenship Or Place Of Organization: United States of America - ------------------------------------------------------------------------------- NUMBER OF SHARES 5) Sole Voting Power: 1,403,536 Shares BENEFICIALLY OWNED -------------------------------------------- BY EACH REPORTING 6) Shared Voting Power: 334,223 Shares PERSON WITH -------------------------------------------- 7) Sole Dispositive Power: 1,403,536 Shares -------------------------------------------- 8) Shared Dispositive Power: 334,223 Shares - ------------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned By Each Reporting Person: 1,737,759 Shares(1) - ------------------------------------------------------------------------------- 10) Check Box If The Aggregate Amount In Row (9) Excludes Certain Shares |_| (See Instructions) - ------------------------------------------------------------------------------- 11) Percent of Class Represented by Amount in Row (9): 12.4% of Common Stock - ------------------------------------------------------------------------------- 12) Type of Reporting Person (See Instructions) IN - ------------------------------------------------------------------------------- (1) Represents (a) 860,502 shares of common stock directly beneficially owned by Dr. Bollon; (b) 217,223 shares of common stock directly beneficially owned by Biogress LLC, of which Dr. Bollon is a founding member and has 50% voting power; (c) 117,000 shares of common stock directly beneficially owned by relatives of Dr. Bollon; and (d) options to purchase 543,034 shares of common stock directly beneficially owned by Dr. Bollon which vest within 60 days of the date hereof. 2 ITEM 1(a). Name of Issuer: Hemobiotech, Inc. ITEM 1(b). Address of Issuer's Principal Executive Offices: 14221 Dallas Parkway, Suite 1500, Dallas, Texas 75254 ------------------------------------------------------------------- ITEM 2(a). Names of Persons Filing: Dr. Arthur Bollon ("Bollon") ------------------------------------------------------------------- ITEM 2(b). Address of Principal Business Office Or, If None, Residence: c/o Hemobiotech, Inc., 14221 Dallas Parkway, Suite 1500, Dallas, Texas 75254 ------------------------------------------------------------------- ITEM 2(c). Citizenship: Bollon is a citizen of the United States of America ------------------------------------------------------------------- ITEM 2(d). Title of Class of Securities: Common Stock, $.001 Par Value Per Share ------------------------------------------------------------------- ITEM 2(e). CUSIP Number: 42368P102 ITEM 3. If this Statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is: None of the reporting persons is an entity specified in Rule 13d-1(b)(1)(ii). ITEM 4. Ownership: (a) Amount beneficially owned by all reporting persons: 1,737,759 Shares (b) Percent of class: 12.4% of Common Stock (c) Number of shares as to which the reporting persons have: (i) sole power to vote or to direct the vote: 1,403,536 Shares (ii) shared power to vote or to direct the vote 334,223 (iii) sole power to dispose or to direct the disposition: 1,403,536 Shares (iv) shared power to dispose or to direct the disposition 334,223 ITEM 5. Ownership of five percent or less of a class. Not applicable. 3 ITEM 6. Ownership of more than five percent on behalf of another person. Not applicable. ITEM 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company. Not applicable. ITEM 8. Identification and classification of members of the group. None of the reporting persons who have filed this schedule is a person, as defined in Rule 13d-1(b)(1)(ii), promulgated pursuant to the Securities Exchange Act of 1934. ITEM 9. Notice of dissolution of group. Not applicable. 4 ITEM 10. Certifications. Not applicable. Dated: February 14, 2006 /s/ Arthur Bollon ------------------------------ Arthur Bollon 5 -----END PRIVACY-ENHANCED MESSAGE-----